Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Autor: Carlino MS; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia., Todd JR; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Gowrishankar K; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Mijatov B; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Pupo GM; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Fung C; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Snoyman S; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia., Hersey P; Kolling Institute of Medical Research, University of Sydney, St. Leonards, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia., Kefford RF; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia., Rizos H; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address: helen.rizos@sydney.edu.au.

Publikováno v: Molecular oncology [Mol Oncol] 2014 May; Vol. 8 (3), pp. 544-54. Date of Electronic Publication: 2014 Jan 15.

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

Autor: Gowrishankar K; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute and Melanoma Institute Australia, Westmead Hospital, Westmead, New South Wales, Australia., Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2012 Jul; Vol. 132 (7), pp. 1850-9. Date of Electronic Publication: 2012 Mar 22.